Clinical Trials Directory

Trials / Completed

CompletedNCT02922790

Feasibility and Smokers' Reactions to DNA Feedback

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
39 (actual)
Sponsor
Duke University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to explore how feedback of cellular DNA (Deoxyribonucleic Acid) damage, as a marker of exposure to the genotoxic agents of tobacco smoke, promotes cessation.

Detailed description

The study aims to recruit 50 smokers who are not engaged in quitting. The study will involve two in-person visits. During visit 1, participants will complete a baseline survey and have their blood drawn. Approximately two weeks later, in visit 2, smokers will be randomized in a 1:2:2 ratio to one of three arms: 1. education about harms of smoking (control group); 2. same education plus information on DNA damage and biomarker feedback (biomarker arm) without visual of damage; or 3. same as arm 2 except accompanied with visuals of participants' normal and DNA damage cells. Participants in the this arm will be informed of their proportion of leucocytes showing DNA damage with pictures of their normal and damaged cells. The goal of the analyses is to obtain effect size estimates (direction, confidence intervals) to inform if results align with hypotheses and obtain insights about reactions about the feedback (Aim 1). The study will collect feasibility data from baseline to three months (e.g., percentage who show up to the sessions, attrition).

Conditions

Interventions

TypeNameDescription
BEHAVIORALstandard health informationSubjects will review standard health information
BEHAVIORALstandard health information plus info. on DNA damageSubjects will review standard health information and information on DNA damage
BEHAVIORALSubjects will review standard health information and information on DNA damage, plus pictures of their DNA damageSubjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage

Timeline

Start date
2017-02-14
Primary completion
2017-07-24
Completion
2017-07-24
First posted
2016-10-04
Last updated
2018-01-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02922790. Inclusion in this directory is not an endorsement.